228 related articles for article (PubMed ID: 26824699)
1. Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis.
Hu M; Hu Y; He J; Li B
PLoS One; 2016; 11(1):e0147374. PubMed ID: 26824699
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.
Hu XY; Zhang W; Hu Y; Zhang Y; Gong R; Liang JY; Liu L
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):313-320. PubMed ID: 27376797
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.
Wang X; Zhao H; Lv L; Bao L; Wang X; Han S
Sci Rep; 2016 Jan; 6():19239. PubMed ID: 26754405
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis.
Zhang Z; Wang T; Zhang J; Cai X; Pan C; Long Y; Chen J; Zhou C; Yin X
PLoS One; 2014; 9(8):e106053. PubMed ID: 25162713
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Bremnes RM; Camps C; Sirera R
Lung Cancer; 2006 Feb; 51(2):143-58. PubMed ID: 16360975
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysis.
Wang Z; Wang Y; Zhang X; Zhang T
Clin Chim Acta; 2018 Nov; 486():303-310. PubMed ID: 30138620
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Pretreatment D-Dimer Level in Small-Cell Lung Cancer: A Meta-Analysis.
Li J; Wang Y; Li J; Che G
Technol Cancer Res Treat; 2021; 20():1533033821989822. PubMed ID: 33563114
[TBL] [Abstract][Full Text] [Related]
10. KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Ardeshir-Larijani F; Bhateja P; Lipka MB; Sharma N; Fu P; Dowlati A
Clin Lung Cancer; 2018 Jul; 19(4):e489-e501. PubMed ID: 29627316
[TBL] [Abstract][Full Text] [Related]
11. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis.
Ueno K; Inoue Y; Kawaguchi T; Hosoe S; Kawahara M
Lung Cancer; 2001; 31(2-3):213-9. PubMed ID: 11165400
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Diabetes Mellitus on Lung Cancer Prognosis: A PRISMA-compliant Meta-analysis of Cohort Studies.
Zhu L; Cao H; Zhang T; Shen H; Dong W; Wang L; Du J
Medicine (Baltimore); 2016 Apr; 95(17):e3528. PubMed ID: 27124062
[TBL] [Abstract][Full Text] [Related]
13. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures.
Tong J; Sun X; Cheng H; Zhao D; Ma J; Zhen Q; Cao Y; Zhu H; Bai J
Lung Cancer; 2011 Nov; 74(2):155-63. PubMed ID: 21621871
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis.
Zhang J; Gu Y; Liu X; Rao X; Huang G; Ouyang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32696952
[TBL] [Abstract][Full Text] [Related]
16. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
Xia H; Shen J; Hu F; Chen S; Huang H; Xu Y; Ma H
Clin Chim Acta; 2017 Jun; 469():191-194. PubMed ID: 28188721
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Fan G; Zhang K; Ding J; Li J
Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
[TBL] [Abstract][Full Text] [Related]
19. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer.
Xu Y; Xu L; Qiu M; Wang J; Zhou Q; Xu L; Wang J; Yin R
Sci Rep; 2015 Apr; 5():9444. PubMed ID: 25901419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]